FFM
TRVI icon

Fairmount Funds Management’s Trevi Therapeutics TRVI Stock Holding History

Fairmount Funds Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,163,287
Closed -$11.3M – 20
2023
Q3 		$11.3M Sell
5,163,287
-27,073
-0.5% -$61.2K 1.35% 17
2023
Q2 		$12.4M Sell
5,190,360
-506,155
-9% -$1.28M 1.75% 14
2023
Q1 		$10.5M Hold
5,696,515
– – 1.81% 15
2022
Q4 		$11M Hold
5,696,515
– – 1.74% 13
2022
Q3 		$8.77M Buy
5,696,515
+4,072,126
+251% +$13.4M 1.54% 21
2022
Q2 		$4.57M Buy
+1,624,389
New +$3.99M 1.04% 22

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

Fairmount Funds Management's TRVI Position: Q4 2023 in Review

Fairmount Funds Management sold out of Trevi Therapeutics (TRVI) in Q4 2023, closing a stake of 5,163,287 shares — an estimated $11.3M sold.

Fairmount Funds Management first reported a position in TRVI in Q2 2022 and held it in 6 quarters. The position peaked at $12.4M in Q2 2023. 63 funds tracked by Wall St. Rank hold TRVI as of Q4 2023.

  • Fairmount Funds Management reported no remaining Trevi Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Fairmount Funds Management sold 5,163,287 Trevi Therapeutics shares in Q4 2023, an estimated $11.3M.
  • Fairmount Funds Management first reported a position in Trevi Therapeutics in Q2 2022 and held it in 6 quarters.
  • Fairmount Funds Management's Trevi Therapeutics position peaked at $12.4M in Q2 2023.
  • 63 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2023.

Based on Fairmount Funds Management's 13F filing for Q4 2023, filed 14 Feb 2024.